Spiro George Rombotis Net Worth

The estimated Net Worth of Spiro George Rombotis is at least $868 Thousand dollars as of 21 December 2023. Mr Rombotis owns over 6,070 units of Cyclacel Pharmaceuticals Inc stock worth over $74,837 and over the last 19 years he sold CYCC stock worth over $20,875. In addition, he makes $772,644 as Pres and CEO & Exec. Director at Cyclacel Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Rombotis CYCC stock SEC Form 4 insiders trading

Mr has made over 24 trades of the Cyclacel Pharmaceuticals Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he bought 6,070 units of CYCC stock worth $20,152 on 21 December 2023.

The largest trade he's ever made was buying 100,000 units of Cyclacel Pharmaceuticals Inc stock on 21 May 2013 worth over $300,000. On average, Mr trades about 11,301 units every 143 days since 2006. As of 21 December 2023 he still owns at least 68,658 units of Cyclacel Pharmaceuticals Inc stock.

You can see the complete history of Mr Rombotis stock trades at the bottom of the page.

Mr. Spiro George Rombotis biography

Spiro George Rombotis is the Pres, CEO & Exec. Director at Cyclacel Pharmaceuticals Inc.

What is the salary of Mr Rombotis?

As the Pres and CEO & Exec. Director of Cyclacel Pharmaceuticals Inc, the total compensation of Mr Rombotis at Cyclacel Pharmaceuticals Inc is $772,644. There are no executives at Cyclacel Pharmaceuticals Inc getting paid more.

How old is Mr Rombotis?

Mr Rombotis is 62, he's been the Pres and CEO & Exec. Director of Cyclacel Pharmaceuticals Inc since . There are 2 older and 3 younger executives at Cyclacel Pharmaceuticals Inc. The oldest executive at Cyclacel Pharmaceuticals Inc is Dr. Robert Westwood Ph.D., 77, who is the Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel..

What's Mr Rombotis's mailing address?

Spiro's mailing address filed with the SEC is C/O CYCLACEL PHARMACEUTICALS, INC.,, 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS, NJ, 07922.

Insiders trading at Cyclacel Pharmaceuticals Inc

Over the last 19 years, insiders at Cyclacel Pharmaceuticals Inc have traded over $6,366,241 worth of Cyclacel Pharmaceuticals Inc stock and bought 3,400,245 units worth $14,147,428 . The most active insiders traders include Capital Ltd Portfolio Servi..., Austin W & Greenhouse David..., and Kevin Ctang Capital Managem.... On average, Cyclacel Pharmaceuticals Inc executives and independent directors trade stock every 78 days with the average trade being worth of $115,984. The most recent stock trade was executed by Paul Mc Barron on 21 December 2023, trading 1,886 units of CYCC stock currently worth $6,262.

What does Cyclacel Pharmaceuticals Inc do?

cyclacel limited is a pharmaceuticals company located in 46-48 e smithfield, london, united kingdom.

Complete history of Mr Rombotis stock trades at Cyclacel Pharmaceuticals Inc

Cyclacel Pharmaceuticals Inc executives and stock owners

Cyclacel Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Spiro George Rombotis,
  Pres, CEO & Exec. Director
• Dr. Judy H. Chiao,
  VP of Clinical Devel. & Regulatory Affairs
• Paul McBarron,
  Exec. VP, CFO, COO, Sec. & Exec. Director
• Dr. Mark H. Kirschbaum M.D.,
  Sr. VP & Chief Medical Officer
• Dr. Robert Westwood Ph.D.,
  Head of Preclinical Devel. and VP of Chemistry & Preclinical Devel.
• Gill Christie,
  Director of HR
• Gregory T. Hradsky,
  Director
• Kevin Ctang Capital Managem...,
  
• Judy Chiao,
  V.P., Clin. Dev. & Reg. Aff.
• Nicholas G Bacopoulos,
  Director
• Christopher S Henney,
  Director
• David C Uprichard,
  Director
• Lloyd Sems,
  Director
• Sam L Barker,
  Director
• John Michael Middlecott Banham,
  Director
• Spiro George Rombotis,
  President and CEO
• Capital Ltd Portfolio Servi...,
  
• Robert J. Spiegel,
  Director
• Brian Schwartz,
  Interim Chief Medical Officer
• Daniel K Spiegelman,
  Director
• Austin W & Greenhouse David...,
  10% owner
• Stanley Morgan,
  10% owner
• Robert Edward Sosnowski,
  VP, Marketing & Sales
• James Edeerfield Capital Lp...,
  
• Willian Collins,
  General Manager
• Gregory Reyes,
  Senior VP, Research
• Pierre Legault,
  Director
• John Gordon Mc Vie,
  Director
• Robert Westwood,
  V.P., Chem. & Preclin. Dev.
• Jean Deleage,
  
• Robert Jackson,
  S.V.P. & Chief Scientific Offi
• Mark Kirschbaum,
  Chief Medical Officer
• Paul Mc Barron,
  See Remarks
• Karin L Walker,
  Director
• Kenneth M. Ferguson,
  Director